ArticleBMC medical imaging2025
CT-derived myosteatosis for baseline risk stratification of cardiotoxicity in patients with diffuse large B-cell lymphoma receiving anthracyclines.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBaseline Risk Stratification for cancer therapy–related cardiac dysfunction (CTRCD) in patients with diffuse large B-cell lymphoma (DLBCL) receiving anthracyclines is crucial. Whether CT-derived myosteatosis can be used for baseline risk stratification of CTRCD in these patients remains unclear. This study aimed to investigate the significance of staging CT-derived myosteatosis in baseline risk stratification of CTRCD in patients with DLBCL receiving anthracyclines.
methodsPatients with DLBCL receiving anthracyclines from two hospitals were retrospectively enrolled. CT body composition variables were measured at the third lumbar vertebra using staging CT. Myosteatosis was identified by the lowest gender-specific quartile of skeletal muscle density. Associations between CT body composition variables and CTRCD, as well as all-cause mortality were analyzed using binary logistic regression and Cox regression analysis, respectively. The performance of these variables for predicting CTRCD was assessed by receiver operating characteristic analysis. The DeLong test was used to compare the area under the receiver operating characteristic curve (AUC) of each variable.
resultsA total of 723 patients (392 male) were included. During a median follow-up of 65 months (IQR, 53–76 months), 180 patients developed CTRCD and 269 patients died. Individuals with myosteatosis (skeletal muscle density ≤ 18.7 HU for female or ≤ 27.8 HU for male) had 3.382 times higher odds of developing CTRCD compared to those without (95% CI: 1.294–7.556). The AUC of the combination of myosteatosis and heart failure association–international cardio-oncology society (HFA-ICOS) score for predicting CTRCD was higher than myosteatosis or HFA-ICOS score [0.828 (95% confidence interval (CI): 0.798, 0.855) vs. 0.719 (95%CI: 0.685, 0.751) vs. 0.586 (95%CI: 0.549, 0.622), all P < 0.001]. Myosteatosis was associated with all-cause mortality (Hazard ratio: 2.015, 95% CI: 1.360–2.994).
conclusionsCT-derived myosteatosis was an independent predictor of CTRCD and all-cause mortality in DLBCL patients treated with anthracyclines and improved baseline risk stratification of CTRCD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.